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ABSTRACT
Objectives We report the use of difference in
differences (DiD) methodology to evaluate a
complex, system-wide healthcare intervention. We
use the worked example of evaluating the Marie
Curie Delivering Choice Programme (DCP) for
advanced illness in a large urban healthcare
economy.
Methods DiD was selected because a randomised
controlled trial was not feasible. The method allows
for before and after comparison of changes that
occur in an intervention site with a matched control
site. This enables analysts to control for the effect of
the intervention in the absence of a local control.
Any policy, seasonal or other confounding effects
over the test period are assumed to have occurred in
a balanced way at both sites. Data were obtained
from primary care trusts. Outcomes were place of
death, inpatient admissions, length of stay and costs.
Results Small changes were identified between
pre- and post-DCP outputs in the intervention site.
The proportion of home deaths and median cost
increased slightly, while the number of admissions
per patient and the average length of stay per
admission decreased slightly. None of these changes
was statistically significant.
Conclusions Effects estimates were limited by small
numbers accessing new services and selection bias
in sample population and comparator site. In
evaluating the effect of a complex healthcare
intervention, the choice of analysis method and
output measures is crucial. Alternatives to
randomised controlled trials may be required for
evaluating large scale complex interventions and the
DiD approach is suitable, subject to careful selection
of measured outputs and control population.
INTRODUCTION
In evaluating the effects of complex
healthcare interventions such as large
system service reorganisation, the gold
standard randomised controlled trial is
not always feasible. We report on the use
of difference in differences (DiD) analysis
to assess the effects of the Marie Curie
Delivering Choice Programme (DCP), a
service redesign initiative which aimed to
enable people to achieve their preferences
for end-of-life care.1 2 The challenge for
researchers is how to examine rigorously
changes in outputs that arise following
such an intervention. Simple estimates of
resource use do not improve understand-
ing of change over time and the relation
to causality, be it complexity of illness,
individual need or preference, or the
choices that are available through new
models of care. In addition, in the UK
there have been a number of recent
government-led initiatives that influence
ongoing change in end-of-life care such
as the Department of Health National
Cancer Plan,3 national service framework
strategies for non-cancer conditions,4 5
the Department of Health End of Life
Care Strategy6 and strategic changes in
end-of-life care investment patterns.
Against this complex and changing back-
ground, simple before and after analysis
of resource use by an end-of-life popula-
tion is not informative. In addition, the
numbers of patients participating in and
affected by local service redesign initia-
tives are often small and may be subject
to a range of selection biases.
We chose to explore the use of DiD
analysis. This method is used to investi-
gate the effects of an intervention over
time on two groups, one subject directly
to the intervention and one control
group at a suitably matched comparator
site.7 This allows researchers to control
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for the possibility that both groups have changed over
time for reasons unrelated to the intervention. In
effect, the analysis isolates the impact of the interven-
tion by removing other known or unknown factors
which may have affected either or both groups during
the study period. Such changes might include altera-
tions to national policy or demographics—such as an
ageing population—that would affect the intervention
and comparator populations. If there were no control
group then any changes seen in the intervention
group might be ascribed to the intervention itself
without accounting for the possible effects of other
factors.
Our primary aim was to assess whether DiD is a
suitable and robust approach for identifying signifi-
cant changes in measured outputs following the intro-
duction of a system-wide complex intervention, in this
case the DCP. We compared four measures of output
at intervention and control sites: (1) place of death;
and over the last 8 weeks of life, (2) number of hos-
pital admissions, (3) length of each admission and (4)
the total cost per patient of providing inpatient care.
These measures of outcome were selected according
to the UK policy aims of reducing unnecessary
inpatient admissions at the end of life and supporting
people to be cared for and die in the place of their
choice.
The DCP
This service redesign initiative1 2 aims to improve the
care of people who are dying from all advanced ill-
nesses and increase the opportunities for them to be
cared for and die in the place of their choice. It is a
complex intervention in which a number of compo-
nents in local health systems are adapted to deliver
change. Details of two local service redesigns are pub-
lished elsewhere.2 Examples include introduction of
discharge liaison services, facilitating transfer to home
from hospital using specialised ambulance provision
and rapid response teams to deal with emergencies
arising in the home. The intervention is developed
following theoretical and practical pilot work to assess
the current state of service delivery in that locality, fol-
lowed by consultation with local stakeholders to
devise and refine a menu of new services. These pro-
cesses conform to the guidance proposed by the
Medical Research Council (MRC) on the development
of complex healthcare interventions8 and use action
research to achieve new models of care. The MRC
guidance goes further to suggest ways to assess the
effects of an intervention in practice. During DCP,
much process data is collected. Knowledge of effects
on patient flows and pathways is supplemented by
qualitative data collected from patients and carers to
increase understanding of their experience of the new
service models. Use of DiD may provide a rigorous
quantitative method to assess change in measurable
outputs over time.
Ethical approval for this analysis was obtained from
Oxfordshire Research Ethics Committee B for the
release of anonymised hospital activity data for the
participating primary care trust (PCT) and from a
comparator PCT within a similar site in another city
matched on age, ethnicity and socioeconomic factors.
In this paper, the intervention and comparator site
remain anonymised.
METHODS
Population
All individuals living within the PCT in which the
intervention was delivered were able to access the
intervention. There was no a priori selection of
patients, randomly or otherwise, as the service
redesign was applied across the entire local health
economy. Data on all individuals who died between
April 2006 and March 2008 were obtained from
PCTs at the test site and comparator site, and included
the corresponding hospital admission data. The
control site was chosen to match as closely as possible
the test site to minimise the risk of any bias arising in
the results owing to differences between populations.
Factors that influenced selection of the control site
were the population size and characteristics, and the
Trust’s structural design. Both sites provided anonym-
ous data on admissions and deaths, including place of
death.
We considered hospital use for the last 8 weeks of
life. This time period was chosen to represent the
period during which patients were most likely to
require the end-of-life care services provided through
the DCP. Data on the last 8 weeks of life were
extracted from the data set and costs assigned to
patients on the basis of the Healthcare Resource
Group (HRG) codes.
Difference in differences
The DiD approach was selected as an approach that
allowed for comparisons over time between non-
random populations and7 9 by comparing the treat-
ment group before and after an intervention with a
control group from a suitably matched comparator
control site that did not receive the intervention.10
The DiD analysis is a quasi-experimental method used
to measure the effects of a treatment or intervention
over time. Analysis was undertaken for four outputs
(1) place of death, (2) number of admissions, (3)
length of stay and (4) costs. Data were obtained from
the intervention and control PCTs for all patients who
died 1 year prior to introduction of the intervention
(April 2006–March 2007) and for 1 year afterwards
(April 2007–March 2008).
The analysis is a fixed-effect multiple regression
model. We tested a DiD effect between the interven-
tion and control PCTs for patients aged over 18 years
registered with a general practitioner (GP) within the
PCT between the period April 2006 to March 2008
Research
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using inpatient attendance data supplied by the rele-
vant PCTs and national reference cost data. Patients
without full records available were excluded from the
analysis. Variables (1–3) were calculated for hospital
admissions over the last 8 weeks of life. We considered
hospital activity only within the last 8 weeks for
periods of care which commenced before but over-
lapped the 8 weeks period and adjusted for age, sex
and admission method (elective or non-elective).
We adjusted for time trends and focused at the level
of the month of any observation. This required the
model to account for correlation between months. For
all outputs, fixed effects models with random inter-
cepts were fitted, controlling for autoregression but
not heteroskedacity. This model type can be used with
time-dependent observations and enables any change
due to the intervention to be isolated from changes
that occur over time due to other trends in the data
(eg, an increase in hospital admissions during colder
winter months). A paired Z test was used to test for
statistical significance.
Baseline differences between the populations are
not normally tested using DiD methods. The DiD
approach seeks to measure the effect of a change
while controlling for many unknown factors (unob-
served heterogeneity). Therefore the comparator is
picked based on a priori expectations that it exhibits
similar unknown factors as the intervention. We
measure the effect of the DCP in the intervention site.
The non-intervention site then acts as a proxy control-
ling for the unobserved heterogeneity.
Analysis at the level of the PCT, HRG, age and sex
groups, separately by preintervention and postinter-
vention time period and month allowed for the long-
term growth in costs and attendance numbers, but
assessed the institutional intervention at the level of
the institution at which it occurred. The observational
unit was the averaged output variable per month per
age category (18–108 in categories 5 years wide) per
PCT. For the analysis of bed days and admissions,
HRG was treated as a fixed effect, essentially fitting a
separate model to each HRG within each age and sex
group and PCT. This is a type of case-mix adjustment,
and allowed for the possibility of different intensities
of resource use in different HRGs. Cost data were
summed across HRGs and analysed at the level of age
group, sex and admission method (elective/
non-elective) within PCTs. Costs for the entire study
were estimated using National Health Service (NHS)
national tariffs for 2010–2011.11 No discounting was
required as all costs were estimated using the same
base year.
Serial dependence was fitted as a simple autoregres-
sive model, since there were insufficient time points to
test seasonal effects. A separate seasonal (winter) term
was included in the model to adjust for excessive
attendances in winter. The starting model was fitted
with all possible interactions. Non-significant terms
were removed using backwards stepwise removal, but
the key terms of interest (intervention group, study
period and the interaction of these two terms) were
retained regardless of significance. The interaction of
study period and intervention group constitutes the
DiD effect, adjusted in this case for the growth over
time of attendances within the PCT, and any differ-
ences between significant age and sex groups, and
assessed separately within each HRG.
RESULTS
Descriptive statistics of intervention and control sites
for the four output measures are shown in table 1.
Primary DiD grouped analysis results are presented in
figures 1–4. We present the difference between the
control site and the intervention site at base year,
change in both sites over the study period and the dif-
ference between the two sites at the end of the study
Table 1 Descriptive statistics of intervention and control sites
Intervention site Comparator site
Time period
Preintervention
(April 2006 to
March 2007)
Intervention (April
2007 to March
2008)
Preintervention
(April ‘06 to March
2007)
Intervention (April
‘07 to March ‘08)
Difference in difference
estimator (95% CI)
Total number of deaths 6715 6291 2265 2032 –
Deaths at home
(proportion)
1245 (0.185) 1176 (0.187) 368 (0.162) 333 (0.164) −0.012 (−0.063 to 0.039)
Mean number of
admissions (SD)
0.84 (1.03) 0.82 (0.96) 1.16 (1.22) 1.17 (1.16) 0.085 (−0.061 to 0.231)
Mean length of stay per
patient in days (SD)
9.16 (12.62) 8.66 (21.24) 11.49 (13.18) 11.92 (13.61) 0.176 (−1.301 to 1.654)
Median cost of acute care
admissions (min, max*)
£2592 (£0, £34 595) £2599 (£0, £34 595) £2795 (£0, £18 394) £2852 (£0, £18 304) £215 (−£188 to £620)
Mean cost of acute care
admission (SD)
£2120 (£1112) £2125 (£1116) £3285 (£1956) £3102 (£1534) –
*The estimated maximum cost is based on the maximum length of stay of 56 days of the analysis period for this study. Where stays exceeded 56 days
actual costs will be higher, though they are not considered as they fall outside our study analysis period.
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period. There were small changes following the inter-
vention period in the intervention site. The propor-
tion of home deaths and median cost increased
slightly, while the number of admissions per patient
and the average length of stay per admission decreased
slightly. None of the changes that occurred during the
period of analysis were found to be statistically signifi-
cant when the intervention site was compared with
the control site.
Figures 1–4 show unadjusted results for the
grouped analysis. Data in the figures are presented as
changes over time, with the intervention and control
sites plotted on the same graph. The time point where
the intervention was introduced is marked by the ver-
tical line.
Place of death
Due to restrictions in the data provided by the interven-
tion group PCT, place of death is classified as either a
home death or not a home death (figure 1). An aim of
the DCP was to increase the numbers of people who
were able to die in the place of their choice, working
under the assumption that more people would prefer to
die at home than currently do so.12 There is wide
Figure 2 Average number of admissions per patient in the last 8 weeks of life. DCP, Delivering Choice Programme.
Figure 1 Percentage of deaths that occur at home. DCP, Delivering Choice Programme.
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variation in the number of patients dying at home in
any given month over the analysis time period and there
is no clear trend in place of death over time. It cannot
be concluded that the DCP increased the number of
home deaths in the test site compared with the control.
Average number of admissions
Over time, there was a small but statistically significant
reduction in the average number of admissions per
patient at the test site over the study period (figure 2).
However, when set against the control site, this differ-
ence disappears. It therefore cannot be concluded that
the DCP has reduced the number of admissions per
patient in the last 8 weeks of their life.
Length of stay
A small but significant decrease in length of stay was
observed in the intervention site relative to the
Figure 4 Average cost per admission for patients in the last 8 weeks of life. DCP, Delivering Choice Programme.
Figure 3 Average length of stay in hospital per patient in the last 8 weeks of life. DCP, Delivering Choice Programme.
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control site over the period of the evaluation (figure
3). No statistically significant reduction in length of
stay was observed between the two sites. As with
home deaths and number of admissions, wide
monthly variations are clearly present. It cannot be
concluded that the DCP led to a reduction in length
of stay.
Costs
The DiD shows no statistically significant change
between the sites over the study period (figure 4).
There is a wide difference in mean cost per admission
between the two sites, though the reasons for this are
not clear, nor does such a difference have an impact
on whether costs have changed as a result of the DCP.
As with the other measures of output, it cannot be
concluded that the DCP has led to any changes in the
mean cost of care per admission.
DISCUSSION
The results we present from the DiD analysis do not
suggest that there was any statistically significant dif-
ference between the test site and the comparator site
for any of the measured outputs. That is to say, any
changes observed in the measured outputs during the
study period cannot necessarily be attributed to the
DCP. This is not to say that the DCP has no value or
that it has not improved the care of the dying in the
test site. For example, an evaluation of qualitative evi-
dence collected for two elements of the service
redesign showed that quality of care and patient
choice at the end of life did improve.13
However, the DiD methodology has been demon-
strated as useful in previous studies7 9 and it was an
appropriate method for use in our evaluation.
Designing a study using such a methodology for
evaluation presents difficulties, and choices made
during the study design phase have a significant
impact on the reliability and accuracy of results. This
paper highlights some of these difficulties. Alternative
analytical approaches to DiD analysis may be possible.
Change point detection methods were considered, as
they are suitable for examining whether and when a
change has occurred within a data set. Such an
approach is often used with time series data.14
However it was unsuitable in this context as we antici-
pated large seasonal effects. These seasonal effects
would potentially mask broader changes as data for
only a single year preintervention and postinterven-
tion were available. We are not aware of any add-
itional accurate analytical approaches suitable for our
data and study aims.
The choice of output measures is an important
starting point for any evaluation. In this instance, our
high level quantitative outputs act merely as proxy
measures for the true objective of the DCP—to
provide high quality care for the dying. These outputs
should be considered in conjunction with the
qualitative evidence collected to understand the full
impact of the programme. Three of the outputs
chosen for this analysis, namely place of death,
number of admissions to hospital and length of stay in
hospital, may closely reflect quality of care while the
fourth, costs per hospital admission does not. While
these measures are not a true reflection of patient out-
comes, they do provide important information about
healthcare processes. Although any number of alterna-
tive outcome measures may be considered, the three
process outcomes measured are often accepted as
proxies of clinical outcome in circumstances in pallia-
tive care research where patient reported outcomes
are not available.1 2 It is possible to assume a link
between the negative aspects of processes and an
expected improvement in health outcomes from
changes to the frequency with which individuals
experience each process. In the absence of more
appropriate measures, these three outputs are
adequate, though the strength of the relationship
between changes in each process measure and outputs
is unknown.
Place of death
While it may appear desirable to increase the numbers
who die at home based on the belief that more people
wish to die at home than so do at present,15 place of
death does not necessarily correlate with quality of
death. People may die at home for a variety of reasons.
This analysis found that approximately 19% of patients
in the intervention site died at home; this compares
with survey evidence that as many as 64% of the popu-
lation express a preference for a home death.15 By
simply examining place of death, important information
on the quality of the death may be missed, or worse,
assumed.
Hospital admissions
A reduction in hospital admissions and length of stay
may indicate a better quality death, but not necessarily
better quality care. We have assumed that a reduction in
these measures is desirable. However, it would need to
be shown that patients who spent less time in hospital
achieved better health outcomes and that patients who
would be most appropriately cared for in hospital were
not denied appropriate care. It is outwith the remit of
our analysis to explore these issues; however we recom-
mend that any future evaluation of the DCP or similar
programmes should consider such factors when select-
ing outcome measures at the study design stage.
Costs
Although it is important to understand the cost impli-
cations, inpatient costs are not a good indicator of
effect for the DCP as any change in mean or median
costs cannot be interpreted independently as good or
bad. An increase in mean costs may suggest that the
programme is effective in moving easier to manage
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cases from hospital to home, leaving more compli-
cated, and therefore expensive, patients to remain in
hospital. We do not know whether or not those
patients left in hospital are there appropriately.
Possibly those patients who are easier to care for are
dying at home simply because it is easier to provide a
home death for them. It might also be that costs are
merely shifted from one service provider to another.
If fewer people die in hospital, then more are likely to
die in other settings and must be supported by appro-
priate resources, often provided by social services or
informally by family and carers. If these costs are not
captured in an evaluation, it is difficult to assess
whether or not the intervention represents a good use
of scarce resources. We must conclude that our evalu-
ation of the DCP does not provide the necessary evi-
dence to estimate whether it has provided value for
money for the stakeholders involved.
Selecting outcome measures when studying complex
system-wide interventions is difficult. By their nature,
such interventions are likely to have an impact on a
wide range of factors. Our analytical approach relied
on the use of existing data provided by healthcare
commissioning organisations and so we were limited
by the types of outcomes or outputs we could
measure. Prospective study designs that collect data
directly from patients would be advantageous, as
patient-reported outcomes, and a wide range of clin-
ical data regarding primary, secondary, emergency and
social care service usage and experience could be col-
lected. The down side would be that fewer patients
can typically be recruited given the costs of research
and collecting data directly from people very near the
end of life is challenging. A trade-off must be made
between study power (through a large cohort) and the
details on outcomes it is possible to collect.
Choice of control site
The choice of comparator group in DiD analysis is
crucial. The principle is that when changes that occur in
the control and intervention group are observed, it
cannot be ruled out that they had the same cause—such
as a change in government policy or a change in the
sociodemographic make-up of the population. But
neither can DiD conclusively rule out that the interven-
tion had no effect—correlation is not causation—and if
the changes are in the same direction, this may be the
result of unrelated factors. What can be said is that com-
pared with the control site, the DCP at the intervention
site does not appear to have had any impact on any of
the outputs measured. Such an interpretation of the
result is corroborated by the descriptive statistics, which
do not show any significant change between the prein-
tervention and postintervention outputs.
Data quality
A key complication was the poor quality of the data
provided by the PCTs. At the intervention site,
records of where a patient died were supplied separ-
ately from records on patient hospital admissions.
These data sets were therefore merged using a unique
identifier, in this case the NHS number. However, not
all patient records could be matched in this way and a
number were dropped from the analysis. The total
number of records dropped was small (<1%) relative
to the number of patient deaths that occurred during
the years under analysis and could not have had a sig-
nificant impact on the results. Even if all records were
assumed to be home deaths, these would not be suffi-
cient to show a significant difference in the results.
CONCLUSION
This worked example showed that DiD analysis can
be useful in increasing our understanding of the
effects of multicomponent, complex interventions
when randomised trials are not suitable or feasible but
is limited by the quality of data available for analysis.
Intervention and comparator populations must be
selected carefully to increase confidence that results
are an effect of the interventions and do not arise
from latent differences in the populations being
studied. Careful attention must be paid to selection of
meaningful outcome (output) measures. Researchers
may wish to consider DiD as a methodologically
robust analysis tool when designing evaluations of
service redesign programmes. Additional learning may
be gained from supplementing quantitative outcomes
with qualitative data on patient and carer experiences
of care in test and comparator sites.
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